{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T15:56:48Z","timestamp":1790870208192,"version":"4.1.0"},"reference-count":64,"publisher":"MDPI AG","issue":"9","license":[{"start":{"date-parts":[[2020,9,16]],"date-time":"2020-09-16T00:00:00Z","timestamp":1600214400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCM"],"abstract":"<jats:p>It is widely accepted that disorders of the male (uro)genital tract, such as erectile dysfunction (ED) and benign diseases of the prostate (lower urinary tract symptomatology or benign prostatic hyperplasia), can be approached therapeutically by influencing the function of both the vascular and non-vascular smooth muscle of the penile erectile tissue or the transition zone\/periurethral region of the prostate, respectively. As a result of the discovery of nitric oxide (NO) and cyclic guanosine monophosphate (GMP) as central mediators of penile smooth muscle relaxation, the use of drugs known to increase the local production of NO and\/or elevate the intracellular level of the second messenger cyclic GMP have attracted broad attention in the treatment of ED of various etiologies. Specifically, the introduction of vasoactive drugs, including orally active inhibitors of the cyclic GMP-specific phosphodiesterase (PDE) 5, has offered great advantage in the pharmacotherapy of ED and other diseases of the genitourinary tract. These drugs have been proven efficacious with a fast on-set of action and an improved profile of side-effects. This review summarizes current strategies for the treatment of ED utilizing the application of vasoactive drugs via the oral, transurethral, topical, or self-injection route.<\/jats:p>","DOI":"10.3390\/jcm9092987","type":"journal-article","created":{"date-parts":[[2020,9,16]],"date-time":"2020-09-16T10:30:12Z","timestamp":1600252212000},"page":"2987","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":25,"title":["The Use of Vasoactive Drugs in the Treatment of Male Erectile Dysfunction: Current Concepts"],"prefix":"10.3390","volume":"9","author":[{"given":"George T.","family":"Kedia","sequence":"first","affiliation":[{"name":"Department of Urology &amp; Urological Oncology, Division of Surgery, Hannover Medical School, 30625 Hannover, Germany"},{"name":"Department of Urology, DIAKOVERE GmbH, Friederikenstft Lutheran Hospital, 30171 Hannover, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefan","family":"\u00dcckert","sequence":"additional","affiliation":[{"name":"Department of Urology &amp; Urological Oncology, Division of Surgery, Hannover Medical School, 30625 Hannover, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6320-0956","authenticated-orcid":false,"given":"Dimitrios","family":"Tsikas","sequence":"additional","affiliation":[{"name":"Center of Pharmacology &amp; Toxicology, Core Unit Proteomics, Hannover Medical School, 30625 Hannover, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Armin J.","family":"Becker","sequence":"additional","affiliation":[{"name":"Faculty of Medicine, Academic Hospital Grosshadern, Department of Urology, Ludwig Maximilians University, 81377 Munich, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Markus A.","family":"Kuczyk","sequence":"additional","affiliation":[{"name":"Department of Urology &amp; Urological Oncology, Division of Surgery, Hannover Medical School, 30625 Hannover, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas","family":"Bannowsky","sequence":"additional","affiliation":[{"name":"Imland Hospital, Department of Urology, 24768 Rendsburg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2020,9,16]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"3572","DOI":"10.1111\/j.1743-6109.2010.02062.x","article-title":"Summary of the Recommendations on Sexual Dysfunctions in Men","volume":"7","author":"Montorsi","year":"2010","journal-title":"J. Sex. Med."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1016\/S0022-5347(17)34871-1","article-title":"Impotence and Its Medical and Psychosocial Correlates: Results of the Massachusetts Male Aging Study","volume":"151","author":"Feldman","year":"1994","journal-title":"J. Urol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/S0140-6736(12)60520-0","article-title":"Erectile dysfunction","volume":"381","author":"Shamloul","year":"2013","journal-title":"Lancet"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1016\/S0002-9149(02)03113-2","article-title":"Relation of Erectile Dysfunction to Angiographic Coronary Artery Disease","volume":"91","author":"Solomon","year":"2003","journal-title":"Am. J. Cardiol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1016\/S0302-2838(03)00305-1","article-title":"Erectile Dysfunction Prevalence, Time of on-Set and Association with Risk Factors in 300 Consecutive Patients with Acute Chest Pain and Angiographically Documented Coronary Artery Disease","volume":"44","author":"Montorsi","year":"2003","journal-title":"Eur. Urol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/j.jacc.2003.07.042","article-title":"Impaired Brachial Artery Endothelium-Dependent Vasodilation in men with Erectile Dysfunction and no Other Clinical Cardiovascular Disease","volume":"43","author":"Kaiser","year":"2004","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1097\/FJC.0b013e31815e8514","article-title":"Correlation Between Flow-Mediated Dilation and Erectile Dysfunction","volume":"51","author":"Kovacs","year":"2008","journal-title":"J. Cardiovasc. Pharmacol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1056\/NEJM199201093260203","article-title":"Nitric Oxide as a Mediator of Relaxation of the Corpus cavernosum in Response to Non-Adrenergic, Non-Cholinergic Neurotransmission","volume":"326","author":"Rajfer","year":"1992","journal-title":"N. Engl. J. Med."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1016\/S0022-5347(01)66315-8","article-title":"The rationale for Prostaglandin E1 in Erectile Failure: A Survey of Worldwide Experience","volume":"155","author":"Porst","year":"1996","journal-title":"J. Urol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1136\/bmj.288.6410.9","article-title":"Penile erection: Possible Role for Vasoactive Intestinal Polypeptide as a Neurotransmitter","volume":"288","author":"Ottensen","year":"1984","journal-title":"Br. J. Med."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1097\/00005392-200101000-00079","article-title":"Expression of Different Phosphodiesterase Genes in Human Cavernous Smooth Muscle","volume":"165","author":"Wiedenroth","year":"2001","journal-title":"J. Urol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1016\/j.juro.2012.03.115","article-title":"Avanafil, a Potent and Highly Selective Phosphodiesterase 5 Inhibitor for Erectile Dysfunction","volume":"188","author":"Kotera","year":"2012","journal-title":"J. Urol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"2229","DOI":"10.1016\/j.juro.2012.11.177","article-title":"A phase 3, Placebo Controlled Study of the Safety and Efficacy of Avanafil for the Treatment of Erectile Dysfunction after Nerve Sparing Radical Prostatectomy","volume":"189","author":"Mulhall","year":"2013","journal-title":"J. Urol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1111\/j.1468-3083.2004.00885.x","article-title":"Update on the Oral Treatments for Male Erectile Dysfunction","volume":"18","author":"Kalsi","year":"2004","journal-title":"Eur. Acad. Dermatol. Venereol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1097\/SPC.0000000000000195","article-title":"Erectile Dysfunction after Radical Prostatectomy: Prevalence, Medical Treatments, and Psychosocial Interventions","volume":"10","author":"Emanu","year":"2016","journal-title":"Curr. Opin. Support. Palliat. Care."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"e201423","DOI":"10.1001\/jamanetworkopen.2020.1423","article-title":"Placebo Responses among Men with Erectile Dysfunction Enrolled in Phosphodiesterase 5 Inhibitor Trials: A Systematic Review and Meta-analysis","volume":"3","author":"Stridh","year":"2020","journal-title":"JAMA Netw. Open"},{"key":"ref_17","doi-asserted-by":"crossref","unstructured":"Gul, M., Carvajal, A., Serefoglu, E.C., Minhas, S., and Salonia, A. (2020). European Association of Urology Guidelines for Sexual and Reproductive Health 2020: What is New?. Int. J. Impot. Res.","DOI":"10.1038\/s41443-020-0335-4"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1111\/j.1743-6109.2011.02537.x","article-title":"Ten (10) year Analysis of Adverse Event Reports to the Food and Drug Administration for Phosphodiesterase (PDE) Type 5 Inhibitors","volume":"9","author":"Lowe","year":"2012","journal-title":"J. Sex. Med."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1111\/j.1743-6109.2005.00196.x","article-title":"The Second Princeton Consensus on Sexual Dysfunction and Cardiac Risk: New Guidelines for Sexual Medicine","volume":"3","author":"Jackson","year":"2006","journal-title":"J. Sex. Med."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1016\/j.sxmr.2017.08.001","article-title":"Update on the Safety of Phosphodiesterase Type 5 Inhibitors for the Treatment of Erectile Dysfunction","volume":"6","author":"Yafi","year":"2018","journal-title":"Sex. Med. Rev."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1016\/j.aju.2016.04.002","article-title":"Innovative Trends and Perspectives for Erectile Dysfunction Treatment: A systematic review","volume":"14","author":"Ismail","year":"2016","journal-title":"Arab. J. Urol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"940","DOI":"10.1016\/j.eururo.2006.06.049","article-title":"Combining Testosterone and PDE5 Inhibitors in Erectile Dysfunction: Basic Rationale and Clinical Evidences","volume":"50","author":"Greco","year":"2006","journal-title":"Eur. Urol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/S0090-4295(02)01687-4","article-title":"The Efficacy of Sildenafil Citrate (VIAGRA) in Clinical Populations: An update","volume":"60","author":"Carson","year":"2002","journal-title":"Urology"},{"key":"ref_24","first-page":"S42","article-title":"Vardenafil Improved Erections in Rabbits Longer than Expected from Plasma Half-Life","volume":"14","author":"Bischoff","year":"2002","journal-title":"Int. J. Impot. Res."},{"key":"ref_25","first-page":"224","article-title":"Vardenafil, a New Selective PDE5 Inhibitor, Significantly Improved all IIEF Domains and Showed Favourable Safety Profile in Patients with Erectile Dysfunction over 12 Weeks","volume":"165","author":"Young","year":"2001","journal-title":"J. Urol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1111\/j.1368-5031.2004.00128.x","article-title":"Sustained Efficacy and Tolerability with Vardenafil over Two Years of Treatment in Men with Erectile Dysfunction","volume":"58","author":"Stief","year":"2004","journal-title":"Int. J. Clin. Pract."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"2006","DOI":"10.1016\/S0735-1097(02)02563-9","article-title":"The Effect of Vardenafil, a Potent and Highly Selective Phosphodiesterase-5 Inhibitor for the Treatment of Erectile Dysfunction, on the Cardiovascular Response to Exercise in Patients with Coronary Artery Disease","volume":"40","author":"Thadani","year":"2002","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"1332","DOI":"10.1016\/S0022-5347(05)64442-4","article-title":"Efficacy and Safety of Tadalafil for the Treatment of Erectile Dysfunction: Results of Integrated Analyses","volume":"168","author":"Brock","year":"2002","journal-title":"J. Urol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/S0090-4295(03)00359-5","article-title":"Efficacy of Tadalafil for the Treatment of Erectile Dysfunction at 24 and 36 Houirs after Dosing: A randomized, Controlled Study","volume":"62","author":"Porst","year":"2003","journal-title":"Urology"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"H24","DOI":"10.1016\/S1520-765X(02)90049-0","article-title":"Tadalafil: A Novel Treatment for Erectile Dysfuncion","volume":"4","author":"Guiliano","year":"2002","journal-title":"Eur. Heart J."},{"key":"ref_31","first-page":"S11","article-title":"Pharmacokinetics, Pharmacodynamics, and Efficacy of Phosphodiesterase Type 5 Inhibitors","volume":"104","author":"Sussman","year":"2004","journal-title":"J. Am. Osteopath. Assoc."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/S1569-9056(02)80240-8","article-title":"Selectivity of Sildenafil and other Phosphodiesterase Type 5 Inhibitors against All Human Phosphodiesterase Families","volume":"1","author":"Gebekor","year":"2001","journal-title":"Eur. Urol."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"H32","DOI":"10.1016\/S1520-765X(02)90050-7","article-title":"Overview of the Cardiovascular Effects of Tadalafil","volume":"4","author":"Emmick","year":"2002","journal-title":"Eur. Heart J."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"1801","DOI":"10.1111\/j.1464-410X.2012.11095.x","article-title":"Efficacy and Safety of Avanafil for Treating Erectile Dysfunction: Results of a Multi-Center, Randomized, Double-Blind, Placebo-Controlled Trial","volume":"110","author":"Zhao","year":"2012","journal-title":"BJU Int."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"1122","DOI":"10.1111\/j.1743-6109.2011.02629.x","article-title":"A Randomized, Double-Blind, Placebo-Controlled Evaluation of the Safety and Efficacy of avanafil in subjects with erectile dysfunction","volume":"9","author":"Goldstein","year":"2012","journal-title":"J. Sex. Med."},{"key":"ref_36","first-page":"49","article-title":"Hemodynamic Effects of Co-Administration of Avanafil and Glyceryl Trinitrate","volume":"3","author":"Nehra","year":"2006","journal-title":"J. Sex. Med."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1358\/dot.2012.48.1.1722068","article-title":"Avanafil for the Treatment of Erectile Dysfunction","volume":"48","author":"Segal","year":"2012","journal-title":"Drugs Today"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1016\/j.eururo.2011.03.025","article-title":"Efficacy and Safety of Once-Daily Dosing of Udenafil in the Treatment of Erectile Dysfunction: Results of a Multicenter, Randomized, Double-Blind, Placebo-Controlled trial","volume":"60","author":"Zhao","year":"2011","journal-title":"Eur. Urol."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"2209","DOI":"10.1111\/j.1743-6109.2010.01817.x","article-title":"Efficacy of Udenafil for the Treatment of Erectile Dysfunction up to 12 Hours after Dosing: A Randomized Placebo-Controlled trial","volume":"7","author":"Park","year":"2010","journal-title":"J. Sex. Med."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1038\/sj.ijir.3901331","article-title":"The Effect of DA-8159, a Novel PDE5 Inhibitor, on Erectile Function in the Rat Model of Hypercholesterolemic Erectile Dysfunction","volume":"17","author":"Kang","year":"2005","journal-title":"Int. J. Impot Res."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"2672","DOI":"10.1111\/j.1743-6109.2008.00945.x","article-title":"Efficacy and safety of mirodenafil, a New Oral Phosphodiesterase Type 5 Inhibitor, for Treatment of Erectile Dysfunction","volume":"5","author":"Paick","year":"2008","journal-title":"J. Sex. Med."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1177\/1756287215625408","article-title":"A review of the Efficacy and Safety of Mirodenafil in the Management of Erectile Dysfunction","volume":"8","author":"Cho","year":"2016","journal-title":"Ther. Adv. Urol."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"1928","DOI":"10.1111\/j.1743-6109.2010.01711.x","article-title":"Efficacy and Tolerability of Lodenafil Carbonate for Oral Therapy of Erectile Dysfunction: A Phase III Clinical Trial","volume":"7","author":"Glina","year":"2010","journal-title":"J. Sex. Med."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/j.ejphar.2008.06.055","article-title":"Pharmacological Characterization of a Novel Phosphodiesterase Type 5 (pde5) Inhibitor, Lodenafil Carbonate, on Human and Rabbit Corpus Cavernosum","volume":"591","author":"Toque","year":"2008","journal-title":"Eur. J. Pharmacol."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1016\/j.jsxm.2016.01.016","article-title":"Pharmacotherapy for Erectile Dysfunction: Recommendations from the Fourth International Consultation for Sexual Medicine (ICSM 2016)","volume":"3","author":"Hatzimouratidis","year":"2016","journal-title":"J. Sex. Med."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"1250","DOI":"10.1056\/NEJMoa074311","article-title":"Quality of Life and Satisfaction with Outcome among Prostate Cancer Survivors","volume":"358","author":"Sanda","year":"2008","journal-title":"N. Engl. J. Med."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1038\/nrurol.2014.151","article-title":"Sexual Dysfunction after Cystectomy and Urinary Diversion","volume":"11","author":"Modh","year":"2014","journal-title":"Nat. Rev. Urol."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"1523","DOI":"10.1007\/s00384-017-2826-4","article-title":"Sexual Dysfunction Following Rectal Cancer Surgery","volume":"32","author":"Celentano","year":"2017","journal-title":"Int. J. Colorectal Dis."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"e13078","DOI":"10.1111\/ijcp.13078","article-title":"Real-World Observational Results from a Database of 48 Million Men in the United States: Relationship of Cardiovascular Disease, Diabetes Mellitus and Depression with Age and Erectile Dysfunction","volume":"72","author":"Goldstein","year":"2018","journal-title":"Int. J. Clin. Pract."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.sxmr.2016.07.002","article-title":"Diabetes and Sexuality","volume":"5","author":"Kizilay","year":"2017","journal-title":"Sex. Med. Rev."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1038\/sj.ijir.3900622","article-title":"Epidemiology of Erectile Dysfunction: Results of the Cologne Male Survey","volume":"12","author":"Braun","year":"2000","journal-title":"Int. J. Impot. Res."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1111\/j.1745-7262.2006.00095.x","article-title":"Long-Term Treatment with Intracavernosal Injections in Diabetic Men with Erectile Dysfunction","volume":"8","author":"Perimenis","year":"2006","journal-title":"Asian J. Androl."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1038\/sj.ijir.3901025","article-title":"Long-Term Efficacy and Compliance of Intracorporeal (Ic) Injection for Erectile Dysfunction Following Radical Prostatectomy: SHIM (IIEF-5) A-nalysis","volume":"15","author":"Raina","year":"2003","journal-title":"Int. J. Impot. Res."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"1325","DOI":"10.1016\/S0022-5347(01)62527-8","article-title":"Efficacy and Safety of Transurethral Alprostadil in Patients with Erectile Dysfunction Following Radical Prostatectomy","volume":"160","author":"Costabile","year":"1998","journal-title":"J. Urol."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"2243","DOI":"10.2165\/11641380-000000000-00000","article-title":"Intraurethral Alprostadil for Erectile Dysfunction: A Review of the Literature","volume":"72","author":"Costa","year":"2012","journal-title":"Drugs"},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1185\/030079902125000318","article-title":"MUSE: Clinical experience","volume":"18","author":"Khan","year":"2002","journal-title":"Curr. Med. Res. Opin."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"S38","DOI":"10.1038\/sj.ijir.3900795","article-title":"Rationale for Combination Therapy of Intraurethral Prostaglandin e1 and Sildenafil in the Salvage of Erectile Dysfunction Patients Desiring Non-invasive Therapy","volume":"14","author":"Nehra","year":"2002","journal-title":"Int. J. Impot. Res."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1159\/000020248","article-title":"Initial Results Utilizing Combination Therapy for Patients with a Suboptimal Response to Either Alprostadil or Sildenafil Monotherapy","volume":"38","author":"Mydlo","year":"2000","journal-title":"Eur. Urol."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1111\/j.1743-6109.2008.01118.x","article-title":"Long-Term, Multicenter Study of the Safety and Efficacy of Topical Alprostadil Cream in Male Patients with Erectile Dysfunction","volume":"6","author":"Rooney","year":"2009","journal-title":"J. Sex. Med."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1016\/j.urology.2006.02.027","article-title":"An Integrated Analysis of Alprostadil Topical Cream for the Treatment of Erectile Dysfunction in 1732 Patients","volume":"68","author":"Yeager","year":"2006","journal-title":"Urology"},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1038\/s41443-018-0087-6","article-title":"The Intrameatal Application of Alprostadil Cream (Vitaros) Improves Drug Efficacy and Patient\u2019s Satisfaction: Results from a Randomized, Two-Administration Route, Cross-over Clinical Trial","volume":"31","author":"Cai","year":"2019","journal-title":"Int. J. Impot. Res."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1111\/andr.12683","article-title":"The First-Generation Phosphodiesterase 5 Inhibitors and Their Pharmacokinetic Issues","volume":"7","author":"Zucchi","year":"2019","journal-title":"Andrology"},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.esxm.2017.10.003","article-title":"Edeus, a Real-Life Study on the Users of Phosphodiesterase Type 5 Inhibitors: Prevalence, Perceptions, and Health Care-Seeking Behavior among European Men with a Focus on 2nd Generation Avanafil","volume":"6","author":"Corona","year":"2018","journal-title":"J. Sex. Med."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"1259","DOI":"10.1080\/17425247.2020.1782383","article-title":"Drug Delivery Options and Therapeutic Advances in the Management of Erectile Dysfunction","volume":"17","author":"Grice","year":"2020","journal-title":"Expert. Opin. Drug. Deliv."}],"container-title":["Journal of Clinical Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2077-0383\/9\/9\/2987\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T10:10:24Z","timestamp":1760177424000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2077-0383\/9\/9\/2987"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,9,16]]},"references-count":64,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2020,9]]}},"alternative-id":["jcm9092987"],"URL":"https:\/\/doi.org\/10.3390\/jcm9092987","relation":{},"ISSN":["2077-0383"],"issn-type":[{"value":"2077-0383","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,9,16]]}}}